Segall Bryant & Hamill LLC Trims Position in Zoetis Inc. (NYSE:ZTS)

Segall Bryant & Hamill LLC lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,286 shares of the company's stock after selling 3,242 shares during the period. Segall Bryant & Hamill LLC's holdings in Zoetis were worth $11,452,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the period. Dunhill Financial LLC raised its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares during the last quarter. Asset Planning Inc purchased a new stake in Zoetis during the 4th quarter valued at $58,000. Finally, Quarry LP grew its holdings in Zoetis by 45.9% in the 3rd quarter. Quarry LP now owns 305 shares of the company's stock worth $60,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ZTS. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. Finally, Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $215.90.

Remove Ads

Insider Buying and Selling

In other news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 in the last three months. Insiders own 0.16% of the company's stock.

Zoetis Stock Down 1.2 %

Shares of Zoetis stock traded down $1.99 during midday trading on Friday, hitting $163.03. The company had a trading volume of 1,550,283 shares, compared to its average volume of 2,595,079. The company has a 50 day moving average of $166.40 and a 200 day moving average of $174.55. The stock has a market capitalization of $73.00 billion, a P/E ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.